MEDYSAPIENS
Latest round
- Series A
Last raised
- Mar 2022
Total raised
- $5.7M
Investors
- 3
About MEDYSAPIENS
Based in Seoul, South Korea, and founded in 2016, MedySapiens combines technologies like bioinformatics, and artificial intelligence (AI) to develop a solution for the early diagnosis of rare genetic diseases in newborns. As of March 2022, Sanggoo Kang is the CEO of the company.ssist MedyCVi.ssist Medy4skin is an artificial intelligence system with deep learning technology that helps in evaluating the skin on 4 items like oil/moisture, wrinkles, pores, and tones. NEOseq Action panel provides therapeutics and diagnosis guidance on targeted genetic testing on diseases from actionable genes.ssist MedyCVi is a cloud solution that provides NEOseq_Action panel for neonatal intensive care unit (NICU), allowing healthcare professionals to get better accuracy.
Who invested in MEDYSAPIENS
3 investors across 1 round
See all investors in MEDYSAPIENS
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Mar 9, 2022
Amount
$5.7M
Investors
Questions about MEDYSAPIENS
Who invested in MEDYSAPIENS?
MEDYSAPIENS has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has MEDYSAPIENS raised?
MEDYSAPIENS has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did MEDYSAPIENS last raise money?
MEDYSAPIENS's most recent round on record is a Series A, in Mar 2022.
What does MEDYSAPIENS do?
Based in Seoul, South Korea, and founded in 2016, MedySapiens combines technologies like bioinformatics, and artificial intelligence (AI) to develop a solution for the early diagnosis of rare genetic diseases in newborns.
Where is MEDYSAPIENS headquartered?
MEDYSAPIENS is headquartered in Seoul, South Korea.
Which VCs invest in companies like MEDYSAPIENS?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at MEDYSAPIENS's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like MEDYSAPIENS? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.